Alector and GSK Report Collaboration in Immuno Neurology | #site_titleAlector and GSK Report Collaboration in Immuno Neurology

Alector and GSK Report Collaboration in Immuno Neurology

Alector, Inc. (NASDAQ: ALEC) has reported a strategic global collaboration to develop and commercialize two clinical stage, potential first in class monoclonal antibodies (AL001 and AL101) to elevate progranulin levels (PGRN).  PGRN is key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders making it the most attractive genetically validated targets to develop new immune neurology treatments. 

Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Our focus on human genetics and the science of the immune system gives us unique insights into the potential of targets such as progranulin to help patients with a number of neurodegenerative diseases. Working with Alector’s world class scientists will allow us to investigate the potential of these immuno-neurology therapies to help patients with frontotemporal dementia, a devastating disease without any currently approved treatments, as well as explore the ability to help patients with other neurodegenerative diseases, such as ALS, Parkinson’s and Alzheimer’s.”

Arnon Rosenthal, Ph.D., Chief Executive Officer, Alector, said: “This transformative collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s commitment to immunology and human genetics, proven drug development capabilities and global footprint, to help expand and accelerate the development of our progranulin franchise into large indications, while bolstering the build out of our own late-stage development and commercial capabilities. Importantly, this collaboration is designed to fully support AL001 and AL101’s development and to enable Alector to continue building a fully integrated company as we strive to address the high unmet medical need in patients suffering from neurodegenerative diseases. We are confident that GSK’s extensive experience launching ground-breaking medicines at the intersection of immunology and human genetics, will ensure that AL001 and AL101 are developed to their full potential.”

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!